Diabetes mellitus: Screening and diagnosis

American Family Physician

Volumn 93, Issue 2, 2016, Pages 103-109

  Pippitt, Karly ^a   Li, Marlana ^a   Gurgle, Holly ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL;

AGE; ARTICLE; CLINICAL TRIAL (TOPIC); DIABETES CONTROL; DIABETES MELLITUS; DIET; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMMUNOASSAY; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; RISK FACTOR; SCREENING TEST; UNITED STATES; ANALYSIS; BLOOD; GLUCOSE TOLERANCE TEST; MASS SCREENING; PROCEDURES;

BLOOD GLUCOSE; DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; HUMANS; MASS SCREENING;

EID: 84955161307     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S5-S10.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(suppl 1):S81-S90.
3. Huang ES, Basu A, O’Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009; 32(12):2225-2229.
4. The top 20 in 2000 [Monitor]. Fam Pract Manag. 2002;9(5):26-29.
5. Patel P, Macerollo A. Diabetes mellitus: diagnosis and screening. Am Fam Physician. 2010;81(7):863-870.
6. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care. 2003;26(suppl 1):S21-S24.
7. Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R. Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162(11):765-776.
8. Siu AL. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(11):861-868.
9. Selph S, Dana T, Bougatsos C, Blazina I, Patel H, Chou R. Screening for abnormal glucose and type 2 diabetes mellitus: a systematic review to update the 2008 U.S. Preventive Services Task Force recommendation. Rockville, Md.: Agency for Healthcare Research and Quality; April 2015.
10. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012;380 (9855):1741-1748.
11. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334(7588):299.
12. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
13. Ratner R, Goldberg R, Haffner S, et al.; Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28(4):888-894.
14. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ.2008;336(7654):1180-1185.
15. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2(6): 474-480.
16. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract. 2015;21(suppl 1):1-87.
17. American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care. 2015;38(suppl):S8-S16.
18. Pottie K, Jaramillo A, Lwein G, et al.; Canadian Task Force on Preventive Health Care. Recommendations on screening for type 2 diabetes in adults [published correction appears in CMAJ. 2012;184(16):1815]. CMAJ. 2012;184(15):1687-1696.
19. Makrilakis K, Liatis S, Grammatikou S, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2011;37(2):144-151.
20. Robinson CA, Agarwal G, Nerenberg K. Validating the CANRISK prognostic model for assessing diabetes risk in Canada’s multi-ethnic population. Chronic Dis Inj Can. 2011;32(1):19-31.
21. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes [published correction appears in Diabetes Care. 2000;23(12):1868- 1869]. Diabetes Care. 2000;23(10):1563-1580.
22. Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev. 2011;33:46-62.
23. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011;343:d7163.
24. Mann DM, Bertoni AG, Shimbo D, et al. Comparative validity of 3 diabetes mellitus risk prediction scoring models in a multiethnic US cohort: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2010;171(9):980-988.
25. Takahashi O, Farmer AJ, Shimbo T, Fukui T, Glasziou PP. A1C to detect diabetes in healthy adults: when should we recheck? Diabetes Care. 2010;33(9):2016-2017.
26. Sheffield JS, Butler-Koster EL, Casey BM, McIntire DD, Leveno KJ. Maternal diabetes mellitus and infant malformations. Obstet Gynecol. 2002;100(5 pt 1):925-930.
27. Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001;94(8):435-444.
28. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477-2486.
29. Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med. 2013;159(2):123-129.
30. Sacks DA, Black MH, Li X, Montoro MN, Lawrence JM. Adverse pregnancy outcomes using the International Association of the Diabetes and Pregnancy Study Groups criteria: glycemic thresholds and associated risks. Obstet Gynecol. 2015;126(1):67-73.
31. Committee on Practice Bulletins—Obstetrics. Practice bulletin no. 137: gestational diabetes mellitus. Obstet Gynecol. 2013;122(2 pt 1): 406-416.
32. Centers for Disease Control and Prevention. Gestational diabetes and pregnancy. 2010 http://www.cdc.gov/pregnancy/diabetes-gestational.html. Accessed July 3, 2015.
33. American Academy of Family Physicians. Clinical preventive service recommendation: diabetes, gestational. 2014. http://www.aafp.org/patient-care/clinical-recommendations/all/diabetes.html. Accessed July 2, 2015.
34. Garrison A. Screening, diagnosis, and management of gestational diabetes mellitus. Am Fam Physician. 2015;91(7):460-467.
35. Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care. 2000;23(3):381-389.
36. American Diabetes Association. (11) Children and adolescents. Diabetes Care. 2015;38(suppl):S70-S76.
37. Copeland KC, Silverstein J, Moore KR, et al.; American Academy of Pediatrics. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents [published correction appears in Pediatrics. 2013;131(5):1014]. Pediatrics. 2013;131(2):364-382.
38. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650-2664.
39. American Diabetes Association. (10) Older adults. Diabetes Care. 2015; 38(suppl):S67-S69.
40. Cohen RM, Haggerty S, Herman WH. HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction? J Clin Endocrinol Metab. 2010;95(12):5203-5206.
41. Malkani S, Mordes JP. Implications of using hemoglobin A1C for diagnosing diabetes mellitus. Am J Med. 2011;124(5):395-401.
42. Kilpatrick ES, Bloomgarden ZT, Zimmet PZ. Is haemoglobin A1c a step forward for diagnosing diabetes? BMJ. 2009;339:b4432.
43. Lapolla A, Mosca A, Fedele D. The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nutr Metab Cardiovasc Dis. 2011;21(7):467-475.
44. Nasir NM, Thevarajah M, Yean CY. Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements. Int J Diabetes Dev Ctries. 2010;30(2):86-90.
45. Herman WH, Dungan KM, Wolffenbuttel BH, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(5):1689-1694.
46. Kirk JK, Passmore LV, Bell RA, et al. Disparities in A1C levels between Hispanic and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care. 2008;31(2):240-246.
47. Kirk JK, D’Agostino RB Jr., Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care. 2006;29(9):2130-2136.
48. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c- Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values [published correction appears in Diabetes Care. 2009;32(1):207]. Diabetes Care. 2008;31(8):1473-1478.
49. Picón MJ, Murri M, Muñoz A, Fernández-García JC, Gomez-Huelgas R, Tinahones FJ. Hemoglobin A1c versus oral glucose tolerance test in postpartum diabetes screening. Diabetes Care. 2012;35(8):1648-1653.
50. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism. 2001; 50(9): 1008-1013.
51. Hosszúfalusi N, Vatay A, Rajczy K, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care. 2003;26(2):452-457.
52. Palmer JP, Hirsch IB. What’s in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care. 2003;26(2):536-538.
53. Vermeulen I, Weets I, Asanghanwa M, et al.; Belgian Diabetes Registry. Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care. 2011;34(8):1760-1765.